In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Section D, individuals will get ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or perhaps the participants are unable to tolerate the study drugs. - Participant eaten grapefruit or grapefruit merchandise within three times before the 1st https://clinical-effectiveness-of67912.ampedpages.com/facts-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-revealed-59178394